Perioperative B-Cell-Targeted Therapy for High-Risk Valve Surgery in Active Primary Sjögren's Disease.

Authors

Bing Li, Lili Pan, Hua Liao

Published in

JACC. Case reports. Pages 110573. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

Primary Sjögren's disease (SjD) is a systemic autoimmune disease driven by B-cell dysregulation. Clinically significant valvular involvement is uncommon, and evidence guiding perioperative immunomodulation remains limited.
A 59-year-old woman with SjD and severe aortic stenosis required valve replacement. Preoperative evaluation demonstrated active SjD with elevated inflammatory markers and hypergammaglobulinemia. Following multidisciplinary discussion, telitacicept, corticosteroids, and hydroxychloroquine were initiated before surgery. After improvement in inflammatory activity, the patient underwent aortic valve and ascending aorta replacement. Histopathologic examination showed degenerative valvular changes with focal inflammatory cell infiltration. The postoperative course was uneventful, with normal prosthetic valve function at 1-year follow-up.
This case highlights the challenges of managing severe valvular heart disease in patients with active primary SjD and a multidisciplinary perioperative strategy incorporating B-cell-targeted therapy. Although preoperative immunomodulation may have attenuated the histopathologic evidence of immune-mediated valvular involvement, the case offers insights when guidance is limited.

PMID:
42886139
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.